Establishment of the new molecular therapy for refractory canine bladder transitional cell carcinoma expressed HER-2.

点击翻译按钮获取中文摘要

We found that HER-2 overexpressed at the rate of 100% for canine bladder transitional cell carcinomas. Therefore we carried out research using molecular target therapy that targeted HER-2 as a new treatment for canine transitional cell carcinoma. Primary culturing of the transitional cell carcinoma obtained from canine cases was performed, and property analysis of the cultured cells was performed. As a result, three transitional cell carcinoma cell lines were established. The appearance of gene and protein expression of HER-2 was found for all three cell lines. However, as a result of the anticancer agent sensitivity examination, the anti-HER-2 agent, trastuzumab did not show cell cytotoxicity for transitional cell carcinomas. In vitro evaluation suggested that one of the antitumor effects of trastuzumab for canine transitional cell carcinomas requires an immune system response. Further study is needed to explore this response.